Author(s)

Kentaro Fukushima¹, Hiroshi Sata¹, Masami Imakita², Takahiro Karasuno¹

¹Department of Hematology, Rinku General Medical Center, Izumisano, Osaka, Japan.
²Department of Pathology, Rinku General Medical Center, Izumisano, Osaka, Japan.

A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.

Peripheral T Cell Lymphoma, CD20, PTCL-NOS, Aberrant Expression, Mogamulizumab

Fukushima, K. , Sata, H. , Imakita, M. and Karasuno, T. (2018) Sustained Remission with Mogamulizumab in Peripheral T Cell Lymphoma with Aberrant CD20 Expression: Case Report and Literature Review. Journal of Cancer Therapy, 9, 179-187. doi: 10.4236/jct.2018.93018.